Advanced Practice Midwife in Mishawaka, IN Accepting Medicare

5 Advanced Practice Midwife nurses found. Showing 1 - 5

Jana Schenkel, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 420 W 4th St, Mishawaka, IN 46544 Phone: 574-307-7673    Fax: 574-307-7692

Tamara Ann Mcnally, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 420 W 4th St, Mishawaka, IN 46544 Phone: 574-252-0304

Patricia Jo Chapman, C.N.M Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 611 E Douglas Rd, Suite 408, Mishawaka, IN 46545 Phone: 574-335-6440    Fax: 574-335-0806

Mrs. Judith A. Weaver-yoder, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 420 W 4th St, Mishawaka, IN 46544 Phone: 574-307-7376    Fax: 574-307-7692

Marianne Hoepfner, CNM, MSN Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 420 W 4th St, Suite 100, Mishawaka, IN 46544 Phone: 574-252-0300    Fax: 574-252-0303

News Archive

Air purification technologies to combat SARS-CoV-2

The onset of the COVID-19 pandemic had people sharing an array of strategies for disinfection and disease prevention.

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

Older people, women and minorities enrolled less frequently in lung cancer drug trials

Women, older people and minorities are enrolled less frequently in lung cancer drug trials and the numbers do not reflect the prevalence of lung cancer in these populations, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

CASdetec: new CRISPR-based SARS-CoV-2 detection platform detects nucleic acids with high sensitivity and specificity

To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.

Lung-MAP study: Majority of cancer patients don't understand genomic test results

A majority of cancer patients don't understand key aspects of the genomic test results they receive as participants in biomarker-driven clinical trials, according to a first-of-its-kind pilot study conducted under the Lung Cancer Master Protocol.

Read more Medical News

› Verified 2 days ago